Italian study reveals Real-World impact of targeted leukemia drug
NCT ID NCT03898128
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked back at the medical records of 84 people with acute lymphoblastic leukemia (ALL) who received a drug called anti-CD22 outside of clinical trials. The goal was to see how safe and effective the treatment was in everyday hospital use. Researchers collected information on side effects, survival, and how long patients stayed cancer-free to better understand the drug's real-world benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
84 people
The number who actually took part.
- Started
-
Nov 2019
- Finished
-
Sep 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
ALL patients treated with anti-CD22 immunoconjugate drugs from 1-Jan-2014 to 01-Mar-2019
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patient with ALL according WHO 2016 classification. 2. Patient who received any anti-CD22 immunoconjugate from 2014 to 01-Mar-2019 outside clinical trials. Exclusion Criteria: 1\. Patients who received anti-CD22 treatment within a clinical trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AUSL Romagna
Ravenna, RA, 48121, Italy
-
Azienda ULSS2 Marca Trevigiana
Treviso, TV, 31100, Italy
-
Irst Irccs
Meldola (FC), FC, 47014, Italy
-
Ospedale S. Eugenio
Roma, 00144, Italy
-
ULSS 3 Serenissima
Mestre, Venezia, 30174, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells aim to wipe out stubborn leukemia
- Tweaking donor cells may shield older transplant patients from a dangerous complication
- The immune cells that could make stem cell transplants work better
- Aloe vera mouthwash tested against chemotherapy mouth sores
- Can a Chemo-Only prep beat radiation for childhood leukemia transplants?
- Can a targeted drug hit the mark in Hard-to-Treat blood cancers?